http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1922069-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b04f067358421e8f3cf5f6d8e5313e07 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D257-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-42 |
| filingDate | 2006-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df76163b41295b8a15c0e5da0b4de19a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_692adcd59b04439ad7c8a4c17bd88709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09a0299f3280f74df8fae0a294f54e92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51ab9c16623465c82ef54473a10c36a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01554414e2a64e994345ec6ae5b88c4e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac1c45363378669723f441b7dfd2289b |
| publicationDate | 2008-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1922069-A2 |
| titleOfInvention | Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use |
| abstract | The invention describes compositions and kits comprising at least one nitric oxide enhancing angiotensin II antagonist compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing angiotensin II antagonist compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (1) treating peripheral vascular diseases; (m) treating portal hypertension (o) treating central nervous system disorders; (p) treating metabolic syndrome; and (q) treating hyperlipidemia. The nitric oxide enhancing angiotensin II antagonist compounds comprise at least one nitric oxide enhancing group linked to the angiotensin II antagonist compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed. |
| priorityDate | 2005-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 4862.